Compare MHH & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHH | XBIT |
|---|---|---|
| Founded | 1986 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.6M | 75.0M |
| IPO Year | 2008 | 2015 |
| Metric | MHH | XBIT |
|---|---|---|
| Price | $7.08 | $2.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.5K | ★ 21.9K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $191,371,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | $132.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.51 | $2.09 |
| 52 Week High | $8.38 | $3.61 |
| Indicator | MHH | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 57.67 | 63.09 |
| Support Level | $6.80 | $2.17 |
| Resistance Level | $7.06 | $2.69 |
| Average True Range (ATR) | 0.49 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 73.09 | 74.32 |
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. The IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.